The FDA has placed a clinical hold on a midstage trial of PharmAthene's next-generation recombinant protective anthrax vaccine SparVax rPA. The trial has yet to start patient enrollment "and accordingly there have been no adverse events reported," PharmAthene said. The firm expects to receive within 30 days a letter from the FDA explaining the basis for the clinical hold, the second for the anthrax vaccine in under a year.

Related Summaries